CureVac and MD Anderson enter strategic collaboration to develop novel cancer vaccines

Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need

17-Apr-2024 - CureVac N.V. and The University of Texas MD Anderson Cancer Center announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines. The collaboration creates strong synergies between CureVac’s unique end-to-end capabilities for cancer antigen discovery, mRNA design, ...

CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs

09-Jan-2023 - CureVac N.V. announced positive preliminary data from ongoing Phase 1 clinical programs in COVID-19 and seasonal flu, assessing both modified and unmodified mRNA technology. The tested vaccine candidates are being developed in collaboration with GSK. The preliminary results generated by this ...

CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

Milestone demonstrates CureVac’s continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseases

19-Aug-2022 - CureVac N.V. announced the start of a Phase 1 study of the modified COVID-19 mRNA vaccine candidate CV0501, administered as a booster dose to previous COVID-19 vaccination. Developed in collaboration with GSK, CV0501 is based on CureVac’s second-generation mRNA backbone and is designed to ...

CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate

01-Apr-2022 - CureVac N.V. announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK. The clinical trial is expected to provide valuable data to further evaluate the performance of CureVac’s ...

CureVac starts Phase 1 Study with Multivalent Influenza Vaccine Candidate

Developed in Collaboration with GSK

11-Feb-2022 - CureVac N.V. announced that it has dosed the first participant in a Phase 1 study of its seasonal influenza second-generation mRNA vaccine candidate, CVSQIV, developed in collaboration with GSK. The differentiated multivalent vaccine candidate features multiple non-chemically modified mRNA ...

CureVac’s First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation

01-Jun-2021 - CureVac N.V. announced that the independent Data Safety Monitoring Board (DSMB) has confirmed that the pivotal Phase 2b/3 study (HERALD) for CureVac’s first-generation COVID-19 vaccine candidate, CVnCoV, has passed a first interim analysis at 59 adjudicated COVID-19 cases. The DSMB confirmed that ...

Second-Generation COVID-19 Vaccine Candidate Demonstrates High Immunogenicity Against Virus Variants in Preclinical Study

Fast onset of strong neutralizing antibody titers after first vaccination

14-May-2021 - CureVac N.V. announced together with its collaboration partner GSK, first preclinical data in a rat model, showing that its second-generation COVID-19 vaccine candidate, CV2CoV, induces high levels of antigen production as well as strong and dose-dependent immune responses in vaccinated animals. ...

CureVac’s COVID-19 Vaccine Candidate Demonstrates Protection Against South African Variant in Preclinical Challenge Study

Full protection of immunized mice from infection and mortality during variant challenge infection

24-Mar-2021 - CureVac N.V. announced the publication of preclinical data demonstrating that their COVID-19 vaccine candidate, CVnCoV, protects against challenge infections with the SARS-CoV-2 Variant of Concern B.1.351 (also referred to as the “South African” variant) and a strain of the original SARS-CoV-2 B1 ...

CureVac Expands CVnCoV COVID-19 Vaccine Candidate Clinical Trial Analyses

Impact of new SARS-CoV-2 variants supports specification of select strains for anticipated case-driven interim analysis in pivotal Phase 2b/3 study

23-Mar-2021 - CureVac N.V. announced plans to expand and further specify the protocols of its ongoing late-stage clinical trials with CVnCoV, its COVID-19 vaccine candidate. CVnCoV efficacy is currently being evaluated in the pivotal HERALD Phase 2b/3 trial in Europe and Latin America. Rapid distribution of ...

CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate

Rolling submission with EMA initiated to accelerate time to potential marketing authorization of CVnCoV

15-Feb-2021 - CureVac N.V. announced initiation of a rolling submission with the European Medicines Agency (EMA) for CVnCoV, the company’s mRNA-based COVID-19 vaccine candidate, currently in late-stage clinical testing. The process was initiated when the first data package consisting of CVnCoV pre-clinical ...